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ABSTRACT
Objective To evaluate the long-term net economic
impact of the California Tobacco Control Program.
Methods This study developed a series of dynamic
models of smoking-caused mortality, morbidity, health
status and healthcare expenditures. The models were
used to evaluate the impact of the tobacco control
programme. Outcomes of interest in the evaluation
include net healthcare expenditures saved, years of life
saved, years of treating smoking-related diseases
averted and the total economic value of net healthcare
savings and life saved by the programme. These
outcomes are evaluated to 2079. Due to data limitations,
the evaluations are conducted only for men.
Results The California Tobacco Control Program resulted
in over 700 000 person-years of life saved and over
150 000 person-years of treatment averted for the 14.7
million male California residents alive in 1990. The value
of net healthcare savings and years of life saved resulting
from the programme was $22 billion or $107 billion in
1990 dollars, depending on how a year of life is
discounted. If women were included, the impact would
likely be much greater.
Conclusions The benefits of California’s Tobacco
Control Program are substantial and will continue to
accrue for many years. Although the programme has
resulted in increased longevity and additional healthcare
resources for some, this impact is more than outweighed
by the value of the additional years of life. Modelling the
programme’s impact in a dynamic framework makes it
possible to evaluate the multiple impacts that the
programme has on life, health and medical expenditures.
INTRODUCTION
The California Tobacco Control Program (CTCP)
was established in 19891e3 using a portion of the
tax revenues generated as a result of the Tobacco
Tax and Health Protection Act, Proposition 99.
With an annual budget of roughly $100 million, the
CTCP became the largest comprehensive tobacco
control programme in the world.1e3 The $0.25/
pack increase in tobacco taxes, which funded the
programme went into effect in January 1989.
Several other components were launched in spring
1990: a statewide anti-tobacco media campaign,
community-based interventions and school-based
prevention programmes. From the beginning, the
CTCP has emphasised a strategy of changing social
norms to make tobacco use less desirable, less
acceptable and less accessible.4 5 The ultimate goal
is to reduce tobacco-related diseases, poor health
and deaths in California.6
A number of studies have been undertaken to
evaluate the impact of the CTCP.7e15 Most of them
focused on process indicators such as amount of
funding and the scope of programme implementa-
tion, smoking outcome measures such as per capita
cigarette consumption and smoking prevalence,
and percentage of population protected by smoke-
free homes or workplaces. A few studies examined
the health benefit of the CTCP. Fichtenberg and
Glantz16 found that the CTCP was associated with
an immediate reduction in deaths from heart
disease. Another study reported that from 1989 to
1999, the CTCP was associated with a 6% reduc-
tion in lung cancer incidence.17 Only one study
evaluated the economic effect of the CTCP, esti-
mating that the programme saved $86 billion in
2004 dollars of healthcare expenditures between
1989 and 2004.18 However, the long-term economic
effect of the CTCP, including reduced smoking-
related diseases (SRDs) and reduced smoking-
related deaths, has not been documented.
To the extent that the CTCP successfully reduces
the incidence of SRDs, it would save smoking-
attributable healthcare expenditures (SAEs). The
SAEs in California were estimated at $8.6 billion for
199919 and $8.7 billion for 1993.20 These estimates,
referred to as ‘gross’ SAEs,21 were based on an
annual cost of smoking approach.22 The reduction
in number of premature deaths may impose addi-
tional healthcare expenditures during the prolonged
years of life for people with avoided premature
death. The tobacco industry refers to the potential
saving from premature death as the ‘death
benefit’.23 24 Cost of smoking estimates which take
into consideration the expenditures net of the
death benefit are referred to as ‘net’ SAEs.21
The issue of the ‘gross’ versus ‘net’ SAEs was first
raised by Leu and Schaub.25 They estimated the
lifetime cost of smoking by simulating the medical
cost history of Swiss men with and without ciga-
rette smoking. They concluded that the extra years
of costs experienced by the longer-lived non-
smoking cohort approximately balanced out the
higher costs during each year of the smokers’
shortened lives. Barendregt et al26 used a dynamic
method to estimate the effects of smoking cessa-
tion on healthcare costs over time in Finland and
found that if all smokers quit, healthcare costs
would be lower at first but after 15 years there
would be a net increase in healthcare costs.
Hodgson27 used a life cycle approach to estimate
the lifetime cost of smoking in the US and found
contradictory evidence. His results showed that
ever smokers incurred higher lifetime medical
expenditures than never smokers even after
adjusting for never smokers’ additional years of life.
In the debate over whether to use the ‘gross’ or ‘net’
SAEs, Warner et al21 suggested that the net measure
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is the logically correct one if the question of interest is how
much greater a nation’s healthcare expenditures are with
smoking compared with the absence of smoking.
It is important that evaluations of public health programmes
such as the CTCP consider the impact of the programme over
time and capture the impact on mortality or longevity. For
example, smoking cessation even late in life has been shown to
increase life expectancy.28e30 Excluding this aspect of the
programme from an evaluation is implicitly placing a value of
0 on life. Thus the value of lives saved and prolonged must be
taken into account, in addition to changes in healthcare
expenditures. The objective of this study is to evaluate the long-
term net economic impact of the CTCP using models designed
to capture both these effects.
Because it is virtually impossible to separate the impact of the
tobacco tax increase from the impact of other tobacco control
activities undertaken by the CTCP, we consider them together.
Four outcome measures are considered: (1) years of life saved, (2)
years of treating SRDs averted, (3) net healthcare expenditures
saved after adjusting for additional healthcare expenditures for
people who live longer due to not smoking and (4) total
economic value of net healthcare expenditures saved and years
of life saved. The evaluation is conducted on a cohort consisting
of all men who resided in California in 1990. Since those who
did not take up smoking or who quit smoking due to the CTCP
would enjoy health benefits long into the future, we used an
evaluation period from 1990 through 2079, the year when the
youngest in 1990 would turn age 90.
METHODS
Data sources
This study relies on four data sources.
National Academy of ScienceseNational Research Council
(NAS-NRC) Twin Registry
This is the largest national twin registry in the US. It consists of
adult male twins born between 1917 and 1927 both of whom
served in the military, mostly during World War II. Two ques-
tionnaires were mailed to registry members in 1967e1969 and
1983e1985 to collect information on registrants’ smoking habits
at the time of survey. The registrants’ mortality status was
periodically obtained from the computerised records of the US
Department of Veterans Affairs (DVA),31 32 which was notified
of the death of approximately 98% of World War II veterans by
relatives or morticians who sought to claim a burial allowance.
The Twin Registry data with mortality status followed-up
through November 1999 was used to estimate the dynamic
smoking-attributable mortality model. We did not use the cause
of death information.
National Medical Expenditure Survey (NMES-2)
This is anationalhousehold survey conducted in1987whichcontains
detailed data for 34459 individuals on smoking history, healthcare
utilisation and expenditures, reasons for service use (diagnosis), source
of payment, health status and history of certain diseases.33 The
NMES-2 data were used to estimate the dynamic smoking-attribut-
ablemorbidity, health status and healthcare expendituresmodels.We
adjusted the expenditures to 1990 dollars using the medical care
component of the Consumer Price Index (CPI).35
Tobacco Use Supplement to the Current Population Survey
(TUS-CPS)
This is a national survey targeting adults aged 15 and older. It
is sponsored by the National Cancer Institute and adminis-
tered as part of the CPS, the US Census Bureau’s continuing
labour force survey.34 It contains detailed information cigarette
smoking history and other tobacco use. The sampling design
allows producing state-specific and national estimates.36 37
The 1992/93, 1995/96, 1998/99 and 2001/02 TUS-CPS data
were used to estimate population smoking initiation and
cessation rates for California and other states in the evaluation
analysis.
California Tobacco Survey (CTS)
This is a telephone survey of California residents that collects
information about tobacco use behaviour and tobacco-related
beliefs, attitudes and knowledge.38 39 The 1990 CTS Adult File
(ages 18+), Youth File (ages 12e17) and the child sample (ages
0e11) from the Screener file were used to construct a cohort of
all California male residents aged 0 and older for the evaluation
analysis. The study cohort consisted of a weighted total of
14 711 966 males of age 0 and older.
Statistical analysis
Analyses in this study were conducted using several statistical
software packages. Mathematica40 was used to derive and esti-
mate the dynamic smoking-attributable mortality model and to
predict the four outcome measures. LIMDEP V.8.041 was used to
estimate the dynamic smoking-attributable morbidity, health
status and healthcare expenditures models. SAS/STAT V.8.242
was used to estimate the population smoking initiation and
cessation rates.
Dynamic models of smoking
We developed a series of dynamic models to describe the impact
of smoking on mortality, morbidity, health status and healthcare
expenditures for men aged 40 and older. The lower boundary of
age 40 was chosen because most SRDs begin to appear at this
age. Figure 1 contains a flowchart showing the estimation
process for these models.
The smoking-attributable mortality model
This describes the dynamic relationship between an individual’s
smoking history and his annual probability of death. It is at the
core of all the other models because it yields an estimated index
for an individual’s expected tobacco exposure, given his smoking
history (age started smoking, cigarettes smoked per day, age
quit). Subsequent morbidity, health status and healthcare
expenditures models are all functions of this tobacco exposure
index. These models are dynamic in the sense that the tobacco
exposure index changes as an individual’s smoking behaviour
changes over time.
The dynamic smoking-attributable mortality model begins by
deriving a theoretical distribution of the tobacco exposure index,
which is the solution to a two-equation system of stochastic
differential equations describing the body’s ability to accumu-
late and purge tobacco toxins in relationship to smoking
behaviour and ageing over time.
d½toxcðtÞ=dt ¼ dp ncðtÞ (1)
d½ncðtÞ=dt ¼  g0  g1 toxcðtÞþ sc dWt (2)
The first equation is an instantaneous accounting identity
stating that the time rate of change of cumulative tobacco
exposure for a current smoker (denoted by subscript c) at time t
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is equal to the difference between a smoker ’s momentary intake
of tobacco exposure at time t (ie, the product of tobacco dosage
per pack, d, and packs of cigarettes smoked per day, p) and his
momentary body purging of tobacco toxin at time t, nc(t). The
second equation describes the time rate of change of a current
smoker ’s body purging of tobacco toxin. It is specified as
a function of: (1) a constant, which represents the reduction in
purge ability due to ageing g0, (2) the cumulative tobacco
exposure, g1 toxc(t), with the assumption that the body ’s
purging ability declines with more tobacco exposure and (3) an
instantaneous white noise term, Wt. To simplify the estimation
process, we assume tobacco dosage per pack equals 1 and
tobacco exposure at time 0 is 0.
This two-equation system is the same for former smokers
except that, in equation 1, the momentary exposure term, d p, is
absent and the initial value of momentary body purging at the
time when a former smoker quits has the same expected value as
a current smoker with an identical smoking history. This spec-
ification implies that the tobacco exposure level accumulated in
the body of former smokers would be diminished over time after
they quit smoking.
The solution to equations 1 and 2 describes the expressions of
the expected value and variance of the tobacco exposure index in
the population with the same smoking history.43 Supplemen-
tary appendix 1 derives the full theoretical distribution of this
exposure index in detail.
The third equation in this analysis is a dynamic normal
survival model specified as:
Die ðtÞ ¼ gðtÞ þ zðtÞ (3)
This equation states that the propensity to die by age t, Die*
(t), is the sum of the expected propensity to die by age t, g(t),
and a normally distributed random error term. The term g(t) is
a function of an individual’s age and the expressions of his
expected tobacco exposure index at age t. Based on equation 3,
and the expressions of the expected value and variance of the
tobacco exposure index solved from equations 1 and 2, we
derived the expressions of the hazard rate. Supplementary
appendix 2 contains detailed description for the specification of
equation 3 and the hazard rate formulation. We then estimated
the parameters of the expected tobacco exposure index and the
hazard rates with the maximum likelihood methods using the
NAS-NRC Twin Registry data. Supplementary appendix 3
presents the detailed estimated parameters.
The smoking-attributable morbidity model
This includes two equations describing the propensity of being
‘currently treated’ for two groups of SRDs in a year. The first
equation is for the group of high relative risk SRDs including
lung cancer, laryngeal cancer and chronic obstructive pulmonary
disease.44 The second equation is for the group of low relative
risk SRDs such as coronary heart disease, stroke and all other
SRDs.44 Both equations are specified as a function of individual’s
age and the expected tobacco exposure index. We estimated the
morbidity model with a Probit model45 using the NMES-2 data.
See supplementary appendix 3 for the estimated parameters.
The smoking-attributable health status model
This describes the probability distribution of individual’s self-
reported health status (excellent, good, fair, poor) for individuals
who are not currently treated for any SRDs. It is specified as
a function of an individual’s age and the expected tobacco
exposure index. We estimated the health status model with an
ordered Probit model using the NMES-2 data. See supplemen-
tary appendix 3 for the estimated parameters.
The smoking-attributable healthcare expenditures model
This describes the total healthcare expenditures of an individual
in a year, and is estimated using the NMES-2 data for three
groups of individuals stratified by disease status. For those
currently treated for high relative risk SRDs, an individual’s
expected total expenditures are estimated as the average total
expenditures of all individuals who have the same smoking
status in this group. For those currently treated for low relative
risk SRDs, an individual’s annual total expenditures are
modelled as a function of ever smoker status and his expected
poor health status. This model was estimated using the ordinary
least squares (OLS) method. For those not currently treated for
any SRDs, a two-part model46 is used to describe the propensity
of having healthcare expenditures (first-part model) and the
logarithm of the magnitude of annual expenditures for those
with positive expenditures (second-part model). The first-part
and second-part models are specified as functions of an indi-
vidual’s age, the expected tobacco exposure index, smoking
status and expected poor health status. We estimated the first-
part model with a Probit model and the second-part model with
the OLS method. See supplementary appendix 3 for the model
specification and estimated parameters.
Figure 1 Flowchart of the estimation process for the dynamic models
of smoking. Mortality model: the input includes two key variables for
each respondent, (a) smoking history and (b) mortality status (including
the date of death). From the mortality model, the parameters of the
expected tobacco exposure index and the hazard rate are estimated.
Given these parameters, the expected tobacco exposure index is
derived. Morbidity models (including two models, one for high risk
smoking-related diseases (SRDs) and another for low risk SRDs): the
two key input variables are (a) the expected tobacco exposure index and
(b) the SRDs treatment status. Health status model: the input is the
same as that for the morbidity models. The output is the expected health
status. Healthcare expenditure models (including three models
separately for individuals with high risk SRDs, individual with low risk
SRDs and individuals without SRDs): the input is the same as that for
the morbidity models and for health status model plus two additional
variables, (a) expected health status and (b) smoking history.
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Evaluation of the economic impact of the CTCP
We evaluated the economic impact of the CTCP over the full
life of a cohort of all 1990 California male residents obtained
from the 1990 CTS data. For each year, we estimated two sets
of predictions for each outcome measure. The first set was
estimated under the CTCP (the factual situation). The second
set was estimated under the assumption that the CTCP did not
exist (the counterfactual situation). The effects of the CTCP
were measured as the difference between these two sets of
predictions.25 Specifically, this evaluation consists of three
steps.
Simulate smoking initiation and cessation rates
In order to estimate the two sets of predictions, the population
smoking behaviour of the cohort under the factual and coun-
terfactual situations from 1990 to 2079 was simulated. We
focused on two measures of smoking behaviour: smoking initi-
ation and successful cessation.
We calculated the yearly smoking initiation and cessation
rates during the period of 1981e1999 using the TUS-CPS data.
Never smokers were defined as those who answered ‘no’ to the
question: ‘Have you smoked at least 100 cigarettes in your entire
life?’ Those who answer ‘yes’ were ever smokers. Ever smokers
were asked, ‘How old were you when you started smoking
cigarettes fairly regularly?’ Ever smokers were also asked
whether they currently smoked. If not, they were defined as
former smokers and were further asked: ‘About how long has it
been since you last smoked cigarettes fairly regularly?’ We
adopted previously developed techniques47e52 to calculate yearly
smoking initiation rates and cessation rates. First, we recon-
structed each respondent’s smoking status retrospectively for
each year before the year of the survey, from 1981 to 1999.
Consistent with another recent study, we assumed respondents’
state of residence did not change over time during this recon-
struction period.53 Second, we calculated smoking initiation
rates for three age groups (11e15, 16e18 and 19e22) separately
for California and for all other states by dividing the weighted
number of respondents who started smoking in a given year by
the weighted number of non-smokers in the beginning of that
year. Third, cessation rates were calculated by dividing the
weighted number of long-time quitters with at least 6 months
of abstinence who quit smoking in a given year by the weighted
number of respondents who were current smokers in the
beginning of that year. The cessation rates were calculated for
four age groups (20e34, 35e44, 45e54 and 55+) for California
and all other states. Finally, these crude rates were smoothed
using a 3-year moving average.
For each age group, a time series model of California’s
smoothed initiation (or cessation) rates during 1981e1999 was
specified as a function of all other states’ smoothed initiation (or
cessation) rates, a dummy variable measuring the effect of the
CTCP (value of 1 since 1989; 0 otherwise), and a time trend,
using a method similar to that employed by Fichtenberg and
Glantz.16 By including the rate for all other states in the model,
we controlled for changes in the California rate due to national
changes in risk factors. The simulated initiation (or cessation)
rates under the factual situation were given by the predicted
values from this model, and the simulated initiation (or cessa-
tion) rates under the counterfactual situation were also given by
the predicted values from this model except that the dummy
variable for the CTCP was assumed to be 0 in 1989 and later
years. After 1999, age-specific factual and counterfactual initia-
tion and cessation rates were assumed to be at their respective
1999 levels.
Simulate mortality, morbidity, health status and healthcare
expenditures
The simulated smoking initiation and cessation rates and the
estimated parameters from the dynamic models of smoking
were applied to the California cohort to simulate their lifetime
outcomes under the factual and counterfactual situations. For
each year from 1990 to 2079, we began to simulate who dies or
survives for individuals aged 40 and older. If an individual
survives or is not yet 40 years old, we simulated who takes up or
quits smoking and who remains at their previous year ’s smoking
status, and estimated the expected tobacco exposure index. For
individuals aged 40 and older who survives, we simulated who is
currently treated for high or low relative risk SRDs and who is
not, and for those not treated, what each individual’s expected
health status is. We then predicted each individual’s healthcare
expenditures. All of these simulations were performed under the
factual and counterfactual situations. Supplementary appendix
4 contains details of the design of the simulations.
Estimate the effects of the CTCP on four outcome measures
Given the above simulation results, we used four different
algorithms to estimate the effects of the CTCP on four outcome
measures: (1) years of life saved, (2) years of treating SRDs
averted, (3) net healthcare expenditures saved after adjusting for
additional healthcare expenditures for people who live longer
due to not smoking and (4) total economic value of net
healthcare expenditures saved and years of life saved.
In the first algorithm, an individual is dropped from the
factual and the counterfactual simulations when he dies in
either simulation. Therefore, this algorithm derives ‘gross’
healthcare savings without considering the impact of potential
prolonged years of life due to the CTCP. This is similar to what
is assumed in the annual cost of smoking studies of national and
state estimates of smoking-attributable expenditures.19 20 44 54 55
In the second algorithm, individuals who die in the factual or
counterfactual simulation are still included in the other simu-
lation until they die or reach age 90. Because more individuals
live longer due to the health benefit of the CTCP, those addi-
tional years of life lead to additional healthcare expenditures.
Therefore, this algorithm derives ‘net’ healthcare savings due to
the CTCP, analogous to the lifetime cost of smoking studies,25e27
by taking into account the reduced smoking-attributable health-
care expenditures during the years while people are alive and the
additional non-smoking-related healthcare expenditures during
the prolonged years of life.
The third and fourth algorithms consider the value of lives
saved by the CTCP in addition to net healthcare savings.
Because premature deaths from smoking usually occur among
older people who have relatively low market earnings, we valued
years of life using a willingness-to-pay (WTP) approach. While
early WTP studies implied the value of life ranging from $3
million to $7 million,56 Sloan et al29 used a conservative value of
$100 000 per life year to estimate the economic losses from
smoking-related mortality. We adopted $100 000 per year to
value the life year in 1990 with adjustments depending on each
person’s disease treatment and health status: $100 000 for
excellent health, $80 000 for good health, $50 000 for fair health
and $25 000 for poor health or being treated for SRDs. The only
difference between the third and fourth algorithms is the
discount rate used to calculate the present value of expected life
years saved (see below).
An alternative approach for considering the value of life is to
calculate disability adjusted life years (DALYs) or quality
adjusted life years (QALYs). While formally calculating DALYs
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or QALYs was beyond the scope of our study due to the lack of
data availability, we have taken into account the dimensions of
the quantity and quality of life that DALYs and QALYs capture
by assigning different values for a year of life based on disease
and health status in our third and fourth algorithms.
Discounting
In all four algorithms, the present value of healthcare expendi-
tures saved by the CTCP was estimated by taking into account
discounting as performed in the lifetime costs of smoking liter-
ature.27 29 57 58 First, considering the potential growth in future
healthcare expenditures, we expressed each person’s future
stream of annual healthcare expenditures during his expected
‘lifetime’ from age 40 to age 90 by inflating the 1990 value of the
predicted healthcare expenditure by 2% per year. The growth
rate of 2% is approximately the difference in average annual
growth rate between the CPI for medical care and the CPI for all
urban consumers during 1990e1999.35 Second, this future
stream of predicted expenditures was discounted by the rate of
time preference at 3% per year to derive the present value of the
lifetime expenditures. For any person, the healthcare expendi-
tures saved by the CTCP equalled the present value of the life-
time expenditures under the counterfactual situation minus the
present value of the lifetime expenditures under the factual
situation. Total healthcare expenditures saved for all male Cali-
fornians were obtained by summing savings across individuals,
taking into account sampling weights in the 1990 CTS data.
In the third algorithm, we discounted the value of future life
years by the rate of time preference using 3% per year.59 In the
fourth algorithm, we discounted the value of future life years by
discount rates that approximated the differential probabilities of
death among individuals of different smoking statuses. As an
approximation, we discounted a year of a current smoker ’s life
by 2%, a year of a former smoker ’s life by 1.5% and a year of
a never smoker ’s life by 1%.
RESULTS
The estimated probability of survival given age and smoking
history is illustrated in figure 2. The more exposure to tobacco
a person has had, as measured by number of decades smoked (or
formerly smoked) and by packs per day smoked, the lower the
probability that he will be alive.
Figure 3 shows the observed, predicted and simulated smoking
cessation rates for California males during 1981e1999 for four
age groups. The young adult group (20e34) had the highest
increase in cessation ratesdfrom about 2% in 1981 to over 5% in
1999dand was most responsive to the CTCP in cessation
especially after 1995, as measured by the difference between the
predicted cessation rates under the factual situation and the
simulated cessation rates under the counterfactual situation.
Figure 4 shows the observed, predicted and simulated smoking
initiation rates for three age groups. The initiation rates for
California males were lower than those for all other states,
especially for the group aged 16e18. For the groups aged 11e15
and 19e22, their initiation rates declined noticeably after 1995
and the reduction was related to the implementation of the
CTCP.
Table 1 shows the estimated economic benefits of the Cali-
fornia CTCP for the 1990 cohort followed until death. Almost
three-quarters of a million person-years of life are saved. In
addition, 141 426 person-years of treatment for the high relative
risk SRDs and 16 240 person-years of treatment for the low
relative risk SRDs are averted.
Using our first algorithm, we estimate that the CTCP saved
$1.438 billion dollars (in 1990 dollars) in healthcare costs over
the period from 1990 through 2079. The estimate is statistically
significant at p value <0.05, two-tailed test.
Our second algorithm yields an estimate of ‘net’ healthcare
savings from the CTCP, including the additional healthcare
expenditures associated with living longer due to the CTCP. The
present value of the net savings for healthcare expenditures was
estimated as 0.144 billion (in 1990 dollars), but is not statis-
tically significant.
Based on the third and fourth algorithms, we derived two
estimates for the total economic value of net healthcare savings
and years of life saved due to the CTCP, valuing a year of life at
$100 000 with adjustments for individual’s disease treatment and
health status. From the third algorithm, our estimated present
value of the total net healthcare resources saved plus the value of
years of life saved was $22.443 billion (in 1990 dollars). From the
fourth algorithm, we estimated that the CTCP would generate
$107.418 billion (in 1990 dollars) of total savings including net
healthcare saving and the value of life saved. Both estimates are
statistically significant at p value <0.05, two-tailed test.
Figure 2 Probability of survival for
men with different smoking histories.
Seven survival curves denote different
smoking histories: n, never smoker;.,
former smoker who smoked 1 pack/day
for 10 years since age 17 and quit at
age 27; $e$, former smoker who
smoked 1 pack/day for 20 years since
age 17 and quit at age 37; e e,former
smoker who smoked 1 pack/day for
30 years since age 17 and quit at age
47; 5, current smoker who smoked
0.5 pack/day since age 17; 1, current
smoker who smoked 1 pack/day since
age 17; 2, current smoker who smoked
2 pack/day since age 17. Age 17 was
chosen because it is the mean age
when male smokers began to smoke.
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DISCUSSION
Our results highlight the importance of developing a compre-
hensive measure for evaluating the impact of a tobacco control
programme that considers the value of healthcare resources
used, and also the value of years of life saved and of improved
health status associated with not smoking. A comparison of the
‘gross’ healthcare expenditures to the ‘net’ healthcare expendi-
tures shows that when the healthcare costs resulting from
longer life are considered, the healthcare savings from the CTCP
disappear. However, these approaches ignore the value of having
people live longer and healthier. When a value for life is included,
the total economic value of the benefits from the CTCP amounts
to $22.4 billion in 1990 dollars. This is more than a 15-fold
increase over the estimate of the ‘gross’ healthcare savings and
a very different result from the ‘net’ healthcare savings, which
ignore the value of life. This value is equivalent to $35.5 billion
in 2007 dollars (adjusted by the CPI). When an individual’s
probability of death is used to discount the years of life, the
CTCP would generate $107.4 billion in 1990 dollars, a 75-fold
increase over the estimate of the ‘gross’ healthcare savings. This
value is equivalent to $170.2 billion in 2007 dollars. Given that
a key public health outcome is improved health, the value of life
saved and improved health should be central to evaluating the
destructive effects of smoking, the single most important
preventable public health hazard.
During the first decade of the programme, the CTCP spent
about $1.2 billion dollars (A Roeseler, California Department of
Public Health, California Tobacco Control Program, personal
communication, 2005). This is dwarfed by the total economic
value of the net healthcare savings, lives saved and health
improved due to the programme. However, it must be noted
that our estimates result from the combined effect of the
Figure 3 Smoking cessation rates for men in California and all other states by age, 1981e1999. The actual rates (dots) represent the 3-year moving
average of the observed cessation rates for California (CA) and all other states (OTH). The predicted CA rates mean the predicted cessation rates from
the time series model under the factual situation. The simulated CA rates mean the predicted cessation rates from the time series model under the
counterfactual situation.
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tobacco tax increase and other components of the CTCP
including the statewide media campaigns, community-based
interventions and school-based prevention programmes.
There are several limitations to this study. First, women were
not included in the analysis because longitudinal data on female
mortality and smoking were unavailable. However, we postulate
that the economic effects of the CTCP for women would be on
the order of two-thirds the size of the effects for men because
the smoking prevalence rate for women was approximately 69%
of the rate for men in California.19 Thus, the total economic
value of the CTCP including men and women may be consid-
erably larger than our estimates. Further research is needed to
include women in the evaluation so that a fuller understanding
of the importance of tobacco control programmes can be
obtained. Second, for the period from 2000 to 2079, we assumed
that smoking initiation and cessation rates remain at their 1999
levels. For these rates to remain constant beyond 1999, tobacco
control efforts must be sustainable. Future research could
explore how the economic impact of the CTCP is sensitive to
post 1999 smoking rates. Third, in the analyses of yearly
smoking initiation rates and cessation rates, we assumed the
state of residence for the respondents of the TUS-CPS data was
unchanged. A recent study which compared the cessation rates
between California and a group of comparison states pointed
out that a large movement of former smokers from California to
other states during the study period would artificially inflate the
estimated cessation rate in other states, and vice versa.53 Further
research is needed to explore the smoking population’s move-
ment between states so as to determine the direction of
potential bias due to such assumption. Fourth, the simple
specification of a single dummy variable for the CTCP in the
smoking initiation and cessation equations implies that the
effect of the programme was constant over time. However, it
has been reported that the impact of the CTCP on smoking
prevalence rates was stronger during the early 1990s than during
the late 1990s, implying that the impact of the CTCP on
Figure 4 Smoking initiation rates for men in California and all other states by age, 1981e1999. The actual rates (dots) represent the 3-year moving
average of the observed initiation rates for California (CA) and all other states (OTH). The predicted CA rates mean the predicted initiation rates from
the time series model under the factual situation. The simulated CA rates mean the predicted initiation rates from the time series model under the
counterfactual situation.
i74 Tobacco Control 2010;19(Suppl 1):i68ei76. doi:10.1136/tc.2008.029421
Research paper
smoking initiation and cessation rates might not be constant
over time.8 Nevertheless, even with this limitation, our results
are in general consistent with the findings from a study by
Messer and Pierce et al53 which showed that from 1980 to 1999,
cessation rates increased most for the young (age 20e34), and
this age group also showed the greatest difference between
California and the comparison states. Finally, we did not include
any impact of the CTCP on secondhand smoke exposure,
though data have shown a substantial decrease in exposure over
time.
Tobacco control programmes are costly. However, the benefits
of the programmes are substantial and continue to accrue for
many years. Although those who are persuaded not to smoke
will live longer, have better health status and require additional
healthcare resources during their additional years of life, this
impact is outweighed by the value of additional years of life and
better health. Public health programmes need to be evaluated
with healthcare costs, additional years of life and improved
health considered as important outcomes.
Funding This research was funded by the California Tobacco-Related Disease
Research Program under grant 9RT-0157. The grant was awarded competitively and
the funding agency was not involved in any aspect of the research.
Competing interests None.
Contributors All authors made contributions to this paper that justify authorship.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Tobacco Education and Research Oversight Committee (TEROC). Toward
a tobacco-free California: strategies for the 21st century 2000e2003, Jan 2000.
http://www.cdph.ca.gov/programs/Tobacco/Documents/CTCPMasterPlan00-03.pdf
(accessed 2 Aug 2009).
2. Novotny T, Siegel MB. California’s tobacco control saga. Health Aff 1996;60:58e72.
3. Farrelly MC, Pechacek TF, Chaloupka FJ. The impact of tobacco control program
expenditures on aggregate cigarette sales: 1981e2000. J Health Econ
2003;22:843e59.
4. Tobacco Control Section. A model for change: the California experience in tobacco
control. Sacramento, CA: California Department of Health Services, 1998. http://
www.cdph.ca.gov/programs/tobacco/Documents/CTCPmodelforchange1998.pdf
(accessed 2 Aug 2009).
5. Tobacco Education Research and Oversight Committee (TEROC). Confronting
a relentless adversary: a plan for success toward a tobacco-free California 2006-
2008. Sacramento, CA: California Department of Health Services, Mar 2006 http://
ww2.cdph.ca.gov/programs/Tobacco/Documents/CTCPMasterPlan06-08ExecSum.
pdf (accessed 10 Aug 2009).
6. California Department of Public Health, California Tobacco Control Program.
California Tobacco Control Update 2009: 20 Years of Tobacco Control in California:
Sacramento, CA: California Department of Public Health, 2009. http://ww2.cdph.ca.
gov/programs/tobacco/Documents/CTCPUpdate2009.pdf (accessed 10 Aug 2009).
7. Pierce JP, Gilpin EA, Emery SL, et al. Tobacco control in California: Who’s winning
the war? An evaluation of the Tobacco Control Program, 1989-1996. La Jolla, CA:
University of California, San Diego, 1998.
8. Gilpin EA, Emery SL, Farkas AJ, et al. The California tobacco control program:
a decade of progress, results for the California tobacco surveys, 1990-1999. La Jolla,
CA: University of California, San Diego, 2001.
9. Al-Delaimy WD, White MM, Gilmer T, et al. The California tobacco control program:
can we maintain the progress? results from the California tobacco survey, 1990-2005.
vol 1. La Jolla, CA: University of California, San Diego, 2008.
10. Pierce JP, Gilpin EA, Emery SL, et al. Has the California tobacco control program
reduced smoking? JAMA 1998;280:893e9. Erratum in: JAMA 281(1):37.
11. Norman GJ, Ribisl KM, Howard-Pitney B, et al. The relationship between home
smoking bans and exposure to state tobacco control efforts and smoking behaviors.
Am J Health Promot 2000;15:81e8.
12. Rohrbach LA, Howard-Pitney B, Unger JB, et al. Independent evaluation of the
California tobacco control program: relationships between program exposure and
outcomes, 1996-1998. Am J Public Health 2002;92:975e83.
13. Siegel M. The effectiveness of state-level tobacco control interventions: a review of
program implementation and behavioral outcomes. Annu Rev Public Health
2002;23:45e71.
14. Gilpin EA, Messer K, White MM, et al. What contributed to the major decline in per
capita cigarette consumption during California’s comprehensive tobacco control
programme? Tob Control 2006;15:308e16.
15. McCarthy WJ, Dietsch BJ, Dent C, et al. Evaluation of the In-school tobacco use
prevention education program, 2005-2006. Sacramento, CA: California Department of
Public Health, 2008. http://www.cdph.ca.gov/programs/tobacco/Documents/
CTCPTupeReport05-06.pdf (accessed 2 Aug 2009).
16. Fichtenberg CM, Glantz SA. Association of the California Tobacco Control Program
with declines in cigarette consumption and mortality from heart disease. N Engl J
Med 2000;343:1172e5.
17. Barnoya J, Glantz SA. Association of the California Tobacco Control Program with
declines in lung cancer incidence. Cancer Causes Control 2004;15:689e95.
18. Lightwood JM, Dinno A, Glantz SA. Effect of the California Tobacco Control
Program on personal healthcare expenditures. PloS Med 2008;5:e178.
19. Max W, Rice DP, Sung HY, et al. The economic burden of smoking in California. Tob
Control 2004;13:264e7.
20. Miller LS, Zhang X, Rice D, et al. State estimates of total medical expenditures
attributable to cigarette smoking, 1993. Public Health Rep 1998;113:447e58.
21. Warner KE, Hodgson TA, Carroll CE. Medical costs of smoking in the
United States: estimates, their validity, and their implications. Tob Control
1999;8:290e300.
22. Max W. The financial impact of smoking on health-related costs: A review of the
literature. Am J Health Promot 2001;15:321e31.
23. Zeger S, Wyant T, Miller L, et al. Statistical testimony on damages in Minnesota
versus the tobacco industry. In: Gastwirth J, ed. Statistical science in the courtroom.
New York: Springer, 2000:19e55.
24. Rubin DB. Statistical issues. In: Gastwirth J, ed. Statistical science in the courtroom.
New York: Springer, 2000:19e55.
25. Leu RE, Schaub T. Does smoking increase medical expenditures? Soc Sci Med
1983;17:1907e14.
Table 1 Estimated economic impact of the California Tobacco Control
Program (CTCP) over a 90-year evaluation period from 1990 through
2079
Outcome measures Predicted value SE
A. Years of life saved (person-years) 712966* 60590
B. Years of treatment saved (person-years):
High relative risk smoking-related
diseases
141426* 5903
Low relative risk smoking-related
diseases
16240 13617
C. Healthcare expenditures saved (in billions):
Algorithm 1: ‘gross’ healthcare savings
without accounting for the impact of
prolonged years of life due to the CTCP
$1.438* $0.227
Algorithm 2: ‘net’ healthcare savings
after adjusting for additional healthcare
expenditures associated with
prolonged years of life due to the CTCP
$0.144 $0.217
D. Total economic value of ‘net’ healthcare savings and years of life saved, assuming
a year of life is valued at $100 000 with adjustments for disease treatment and health
status (in billions):
Algorithm 3: present value of life years
discounted at 3%
$22.443* $1.118
Algorithm 4: present value of life years
discounted at 2% for current smokers,
1.5% for former smokers and 1% for
never smokers
$107.418* $1.629
All monetary values are in 1990 dollars.
*Statistically significant at p value <0.05, two-tailed test.
What this paper adds
< This paper develops a series of dynamic models of smoking
behavior and consequences that analyze the impact of
smoking initiation and cessation on morbidity, mortality,
health status, and healthcare expenditures over the lifetime of
Californians.
< The models are used to evaluate the impact of the first decade
of the California Tobacco Control Program on males.
< The findings indicate that when the value of increased
longevity is included, the program saved $22e$107 billion,
depending on how life is valued.
Tobacco Control 2010;19(Suppl 1):i68ei76. doi:10.1136/tc.2008.029421 i75
Research paper
26. Barendregt JJ, Bonneu L, Van Der Mass PJ. The health care costs of smoking.
N Engl J Med 1997;337:1052e7.
27. Hodgson TA. Cigarette smoking and lifetime medical expenditure. Milbank Q
1992;70:81e125.
28. Taylor DH, Hasselblad V, Henley SJ, et al. Benefits of smoking cessation for
longevity. Am J Public Health 2002;92:990e6.
29. Sloan FA, Ostermann J, Picone G, et al. The price of smoking. Cambridge, Mass:
MIT Press, 2004.
30. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years’
observations on male British doctors. BMJ 2004;328:1519.
31. Zaretsky M. Communication between identical twins: Health behavior and
social factors are associated with longevity that is greater among identical than
fraternal U.S. World War II veteran twins. J Gerontol A Biol Med Sci
2003;58A:566e72.
32. Hrubec Z, Neel JV. Familial factors in early deaths: twins followed 30 years to ages
51-61 in 1978. Hum Genet 1978;59:39e46.
33. U.S. Department of Health and Human Services (US DHHS). National medical
expenditure survey, 1987: household survey data. Rockville, MD: Agency for Health
Care Policy and Research, 1991.
34. Hartman A, Willis G, Lawrence D, et al. The 1998e1999 NCI tobacco use
supplement to the current population survey (TUS-CPS): representative survey
findings. Bethesda, MD: US Department of Health and Human Services, National
Institutes of Health, National Cancer Institute, 2002.
35. U.S. Department of Labor, Bureau of Labor Statistics, Consumer Price Index
Detailed Report, Table 3A: Consumer Price Index for all Urban Consumers (CPI-U):
U.S. city average, detailed expenditure categories. Various Years. http://www.bls.
gov/cpi/tables.htm.
36. Hansen RH. The current population survey: design and methodology. Washington,
DC: US Dept of Commerce, Bureau of the Census, 1995. Technical paper 40.
37. Shopland DS, Hartman AM, Gibson JT, et al. Cigarette smoking among US adults by
state and region: Estimates from the Current Population Survey. J Natl Cancer Inst
1995;88:1748e58.
38. Burns D, Pierce JP. Tobacco use in California, 1990-1991. Sacramento, California:
Department of Health Services, 1992.
39. Pierce JP, Goodman J, Gilpin EA, et al. Technical report on analytic methods and
approaches used in the Tobacco Use in California, 1990-1991 Report. Sacramento,
California: Department of Health Services, 1992.
40. Wolfram S. The mathematica book. 5th edn. Champaign, IL: Wolfram Media, 2003.
41. Greene WH. LIMDEP, Version 8.0. Plainview, NY: Econometric Software, Inc, 2002.
42. Anon. SAS/STAT user’s guide. Version 8. Cary, NC: SAS Institute Inc, 1999.
43. Oksendal B. Stochastic differential equations: An introduction with applications.
5th edn. NY, NY: Springer, 2000:64e5.
44. Johnson E, Dominici F, Griswold M, et al. Disease cases and their medical costs
attributable to smoking: an analysis of the national medical expenditure survey.
J Econom 2002;112:139e45.
45. McKelvey R, Zavoina W. A statistical model for the analysis of ordinal level
dependent variables. J Math Sociol 1975;4:103e20.
46. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat
Assoc 1983;78:605e10.
47. Lee LL, Gilpin EA, Pierce JP. Changes in the patterns of initiation of cigarette
smoking in the United States: 1950, 1965, and 1980. Cancer Epidemiol Biomarkers
Prev 1993;2:593e7.
48. Pierce JP, Lee L, Gilpin EA. Smoking initiation by adolescent girls, 1944 through
1988. An association with targeted advertising. JAMA 1994;271:608e11.
49. Gilpin EA, Lee L, Pierce JP. Smoking initiation rates in adults and minors: United
States, 1944-1988. Am J Epidemiol 1994;140;535e43.
50. US Centers for Disease Control and Prevention (US CDC). Trends in smoking
initiation among adolescents and young adultsdUnited States, 1980e1989.
MMWR Morb Mortal Wkly Rep 1995;44:521e5.
51. Gilpin EA, Pierce JP. Trends in adolescent smoking initiation in the United States: is
tobacco marketing an influence? Tob Control 1997;6:122e7.
52. Gilpin EA, Pierce JP. Demographic differences in patterns in the incidence of
smoking cessation: United States 1950-1990. Ann Epidemiol 2002;12:141e50.
53. Messer K, Pierce JP, Zhu SH, et al. The California Tobacco Control
Program’s effect on adult smokers: (1) Smoking cessation. Tob Control
2007;16:85e90.
54. Bartlett JC, Miller LS, Rice DP, et al. Medical expenditures attributable to
cigarette smokingdUnited States, 1993. MMWR Morb Mortal Wkly Rep
1994;43:469e72.
55. Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. Soc
Sci Med 1999;48:375e91.
56. Viscusi WK. The value of risks to life and health. J Econ Lit 1993;31:1912e46.
57. Manning WG, Keeler EB, Newhouse JP, et al. The taxes of sin: Do smokers and
drinkers pay their way? JAMA 1989;261:1604e9.
58. Manning WG, Keeler EB, Newhouse JP, et al. The costs of poor health habits.
Cambridge, Mass: Harvard University Press, 1991.
59. Frederick S. Valuing future life and future lives: a framework for understanding
discounting. J Econ Psychol 2006;27:667e80.
i76 Tobacco Control 2010;19(Suppl 1):i68ei76. doi:10.1136/tc.2008.029421
Research paper
